ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ABCL vs LQDA // EV/EBITDA & P/E VALUATION

AbCellera Biologics Inc. (NASDAQ) VS. Liquidia Corporation (NASDAQ) • 15-METRIC TALLY: ABCL 1 — LQDA 8
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABCL VS. LQDA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ABCL LQDA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -20.50% -12.60% -7.90 LQDA /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -4.11% -0.99% -3.12 LQDA /fcf-yield <GO>
Operating Margin -60.00% -32.50% -27.50 LQDA /operating-margins <GO>
Net Profit Margin -60.00% -43.50% -16.50 LQDA /net-margins <GO>
Revenue Growth (YoY) 160.60% 180.00% -19.40 LQDA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 6.60 6.33 +0.27 ABCL /balance-sheet <GO>
Piotroski F-Score Quality 4/9 5/9 -1.00 LQDA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 49.0 52.5 -3.50 LQDA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.90 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 21.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.97B $4.03B -$58.9M LQDA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ABCL REV LQDA REV ABCL GROSS % LQDA GROSS % ABCL FCF LQDA FCF
FY 2025 $75.1M $158.3M — — -$174.1M -$40.0M
FY 2024 $28.8M $14.0M — 58.0% -$187.0M -$98.4M
FY 2023 $38.0M $17.5M — — -$43.9M -$42.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABCL // BETA —
LQDA // BETA 0.90